TECHNICAL ANNEX

**Network meta-analysis**

A network meta-analysis was carried out by pivotal clinical trials of infliximab, adalimumab, golimumab and vedolizumab with data of clinical remission in maintenance stage.

The network meta-analysis was made as recommendations of declaration in Preferred Reporting Items for Systematic reviews and Meta-analysis (PRISMA)[1] and for the International Society for Pharmacoeconomics and Outcomes Research (ISPOR)[2].


It was made by bayesian approach with the statistic programs R- Statistics® and JAGS®. Because of the heterogeneity of studies, it could be analyzed by fixed o randomized model. To determine the most suitable one, it was considered the complexity, the deviation and the value of DIC (Deviance Information Criterion). A 100,000 iteraccions were implemented for each model, and the convergence was analyzed by Brooks-Gelman-Rubin method[3]. And finally, 4 chains of 20,000 samples were analyzed to obtain the subsequent distributions.

For each comparison between treatments, the relative risk (RR) and 95% confidence interval (CI) were calculated.

All of the included studies compare the drug with placebo, and they are very similar in the basal characteristics of patients. Only ULTRA 2 study for adalimumab[4], and GEMINI I for vedolizumab[5] allowed pretreated patients with other biologic drugs for moderate to severe UC. The included patients were adults, with a median age among 38.6 and 42.4 years. The duration of disease in the patients was from 6.2 to 8.5 years.

A fixed model was selected for the assessment of clinical remission at week 52-54. Network meta-analysis results show no statistically significant differences between adalimumab (RR: 0.87; 0.42 to 1.8; CI 95%), golimumab (RR: 0.71; 0.39 to 1.3; CI 95%) and vedolizumab (RR: 1.6; 0.85 to 3.1) versus infliximab. In contrast, statistically significant differences were shown by the comparison of placebo versus infliximab (RR: 0.47; 0.28 a 0.73; CI 95%). Figure S1.

**Figure S1. Clinical remission at 52- 54 weeks fixed effects model**



**REFERENCES**

1. Liberati, A., Altman, D.G., Tetzlaff, J., Mulrow, C., Gøtzsche, P.C., Ioannidis, J.P.A., Clarke, M., Devereaux, P.J., Kleijnen, J., Moher, D.: The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J. Clin. Epidemiol. 62, e1–e34. doi:10.1016/j.jclinepi.2009.06.006

2. Jansen, J.P., Trikalinos, T., Cappelleri, J.C., Daw, J., Andes, S., Eldessouki, R., Salanti, G.: Indirect Treatment Comparison/Network Meta-Analysis Study Questionnaire to Assess Relevance and Credibility to Inform Health Care Decision Making: An ISPOR-AMCP-NPC Good Practice Task Force Report. Value Heal. 17, 157–173 (2015). doi:10.1016/j.jval.2014.01.004

3. Brooks SP, G.A.: General methods for monitoring convergence of iterative simulations. ournal Comput. Graph. Stat. 7, 434–55 (1998)

4. Sandborn, W.J., van Assche, G., Reinisch, W., Colombel, J.-F.J.J.-F., D’Haens, G., Wolf, D.C., Kron, M., Tighe, M.B., Lazar, A., Thakkar, R.B.: Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 142, 253–257 (2012). doi:10.1053/j.gastro.2011.10.032

5. Feagan, B.G., Rutgeerts, P., Sands, B.E., Hanauer, S., Colombel, J.-F.J.-F.J.-F., Sandborn, W.J., Van Assche, G., Axler, J., Kim, H.-J., Danese, S., Fox, I., Milch, C., Sankoh, S., Wyant, T., Xu, J., Parikh, A., Rosario, M., Dirks, N.L., Gastonguay, M.R., Fasanmade, a. a., Wyant, T., Parikh, A., Sandborn, W.J., Feagan, B.G., Reinisch, W., Fox, I., Rutgeerts, P., Sands, B.E., Hanauer, S., Colombel, J.-F.J.-F.J.-F., Sandborn, W.J., Van Assche, G., Axler, J., Kim, H.-J., Danese, S., Fox, I., Milch, C., Sankoh, S., Wyant, T., Xu, J., Parikh, A.: Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis. N. Engl. J. Med. 369, 699–710 (2013). doi:10.1056/NEJMoa1215734

**Treatment regimen**

|  |  |  |
| --- | --- | --- |
| **Drug** | **Induction regimen** | **Maintenance regimen** |
| **Infliximab** | 5 mg/ Kg of body weight at weeks 0, 2 and 6 | 5 mg/ Kg of body weight every 8 weeks |
| **Adalimumab** | 160 mg at week 0  80 mg at week 2 | 40 mg every two weeks |
| **Golimumab** | 200 mg at week 0  100 mg at week 2 | 50 mg every four weeks1  100 mg every four weeks2 |
| **Vedolizumab** | 300 mg at weeks 0, 2, 6 | 300 mg every 8 weeks |
| 1<80 kg of body weight; 2 ≥80 kg of body weight | | |

**Univariant Sensitive Analysis**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **VARIABLE NAME** | **VARIABLE VALUE** | **STRATEGY** | | **COST** | **EFFICACY** | **ICER (vs BASE CASE)** |
| Body weight | 60 | | ADALIMUMAB | 62,767 € | 5.070 QALY | 28,097 €/QALY |
| Body weight | 60 | | GOLIMUMAB | 65,378 € | 5.071 QALY | 25,239 €/QALY |
| Body weight | 60 | | INFLIXIMAB | 88,135 € | 5.973 QALY | --- |
| Body weight | 60 | | VEDOLIZUMAB | 146,985 € | 6.000 QALY | 2,114,617 €/QALY |
| Body weight | 70 | | ADALIMUMAB | 62,767 € | 5.070 QALY | 38,809 €/QALY |
| Body weight | 70 | | GOLIMUMAB | 65,378 € | 5.071 QALY | 35,964 €/QALY |
| Body weight | 70 | | INFLIXIMAB | 97,807 € | 5.973 QALY | --- |
| Body weight | 70 | | VEDOLIZUMAB | 146,985 € | 6.000 QALY | 1,767,106 €/QALY |
| Body weight | 80 | | ADALIMUMAB | 62,767 € | 5.070 QALY | 49,520 €/QALY |
| Body weight | 80 | | GOLIMUMAB | 99,301 € | 5.071 QALY | 9,069 €/QALY |
| Body weight | 80 | | INFLIXIMAB | 107,478 € | 5.973 QALY | --- |
| Body weight | 80 | | VEDOLIZUMAB | 146,985 € | 6.000 QALY | 1,419,595 €/QALY |
| Body weight | 90 | | ADALIMUMAB | 62,767 € | 5.070 QALY | 60,232 €/QALY |
| Body weight | 90 | | GOLIMUMAB | 99,301 € | 5.071 QALY | 19,795 €/QALY |
| Body weight | 90 | | INFLIXIMAB | 117,149 € | 5.973 QALY | --- |
| Body weight | 90 | | VEDOLIZUMAB | 146,985 € | 6.000 QALY | 1,072,084 €/QALY |
| Body weight | 100 | | ADALIMUMAB | 62,767 € | 5.070 QALY | 70,943 €/QALY |
| Body weight | 100 | | GOLIMUMAB | 99,301 € | 5.071 QALY | 30,520 €/QALY |
| Body weight | 100 | | INFLIXIMAB | 126,820 € | 5.973 QALY | --- |
| Body weight | 100 | | VEDOLIZUMAB | 146,985 € | 6.000 QALY | 724,573 €/QALY |
| **VARIABLE NAME** | **VARIABLE VALUE** | | **STRATEGY** | **COST** | **EFFICACY** | **ICER (vs BASE CASE)** |
| Discount rate | 0 | | ADALIMUMAB | 64,998 € | 5.628 QALY | 46,901 €/QALY |
| Discount rate | 0 | | GOLIMUMAB | 67,507 € | 5.628 QALY | 44,391 €/QALY |
| Discount rate | 0 | | INFLIXIMAB | 112,286 € | 6.637 QALY | --- |
| Discount rate | 0 | | VEDOLIZUMAB | 159,416 € | 6.668 QALY | 1,517,880 €/QALY |
| Discount rate | 0.015 | | ADALIMUMAB | 63,842 € | 5.336 QALY | 46,179 €/QALY |
| Discount rate | 0.015 | | GOLIMUMAB | 66,405 € | 5.336 QALY | 43,509 €/QALY |
| Discount rate | 0.015 | | INFLIXIMAB | 107,858 € | 6.289 QALY | --- |
| Discount rate | 0.015 | | VEDOLIZUMAB | 152,928 € | 6.319 QALY | 1,534,548 €/QALY |
| Discount rate | 0.03 | | ADALIMUMAB | 62,767 € | 5.070 QALY | 45,450 €/QALY |
| Discount rate | 0.03 | | GOLIMUMAB | 65,378 € | 5.071 QALY | 42,614 €/QALY |
| Discount rate | 0.03 | | INFLIXIMAB | 103,803 € | 5.973 QALY | --- |
| Discount rate | 0.03 | | VEDOLIZUMAB | 146,985 € | 6.000 QALY | 1,551,649 €/QALY |
| Discount rate | 0.045 | | ADALIMUMAB | 61,765 € | 4.826 QALY | 44,713 €/QALY |
| Discount rate | 0.045 | | GOLIMUMAB | 64,420 € | 4.828 QALY | 41,709 €/QALY |
| Discount rate | 0.045 | | INFLIXIMAB | 100,080 € | 5.683 QALY | --- |
| Discount rate | 0.045 | | VEDOLIZUMAB | 141,531 € | 5.710 QALY | 1,567,704 €/QALY |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Discount rate | 0.06 | ADALIMUMAB | 60,829 € | 4.604 QALY | 43,970 €/QALY |
| Discount rate | 0.06 | GOLIMUMAB | 63,523 € | 4.606 QALY | 40,794 €/QALY |
| Discount rate | 0.06 | INFLIXIMAB | 96,657 € | 5.419 QALY | --- |
| Discount rate | 0.06 | VEDOLIZUMAB | 136,513 € | 5.444 QALY | 1,585,390 €/QALY |
| **VARIABLE NAME** | **VARIABLE VALUE** | **STRATEGY** | **COST** | **EFFICACY** | **ICER (vs BASE CASE)** |
| Age at the onset | 20 | ADALIMUMAB | 62,858 € | 5.085 QALY | 45,485 €/QALY |
| Age at the onset | 20 | GOLIMUMAB | 65,468 € | 5.086 QALY | 42,651 €/QALY |
| Age at the onset | 20 | INFLIXIMAB | 103,919 € | 5.988 QALY | --- |
| Age at the onset | 20 | VEDOLIZUMAB | 147,105 € | 6.016 QALY | 1,551,207 €/QALY |
| Age at the onset | 30 | ADALIMUMAB | 62,842 € | 5.082 QALY | 45,479 €/QALY |
| Age at the onset | 30 | GOLIMUMAB | 65,452 € | 5.084 QALY | 42,645 €/QALY |
| Age at the onset | 30 | INFLIXIMAB | 103,899 € | 5.985 QALY | --- |
| Age at the onset | 30 | VEDOLIZUMAB | 147,084 € | 6.013 QALY | 1,551,181 €/QALY |
| Age at the onset | 40 | ADALIMUMAB | 62,767 € | 5.070 QALY | 45,450 €/QALY |
| Age at the onset | 40 | GOLIMUMAB | 65,378 € | 5.071 QALY | 42,614 €/QALY |
| Age at the onset | 40 | INFLIXIMAB | 103,803 € | 5.973 QALY | --- |
| Age at the onset | 40 | VEDOLIZUMAB | 146,985 € | 6.000 QALY | 1,551,649 €/QALY |
| Age at the onset | 50 | ADALIMUMAB | 62,515 € | 5.028 QALY | 45,370 €/QALY |
| Age at the onset | 50 | GOLIMUMAB | 65,129 € | 5.029 QALY | 42,532 €/QALY |
| Age at the onset | 50 | INFLIXIMAB | 103,487 € | 5.931 QALY | --- |
| Age at the onset | 50 | VEDOLIZUMAB | 146,657 € | 5.959 QALY | 1,551,214 €/QALY |
| Age at the onset | 60 | ADALIMUMAB | 62,038 € | 4.948 QALY | 45,217 €/QALY |
| Age at the onset | 60 | GOLIMUMAB | 64,656 € | 4.950 QALY | 42,372 €/QALY |
| Age at the onset | 60 | INFLIXIMAB | 102,885 € | 5.852 QALY | --- |
| Age at the onset | 60 | VEDOLIZUMAB | 146,031 € | 5.880 QALY | 1,551,453 €/QALY |
| **VARIABLE NAME** | **VARIABLE VALUE** | **STRATEGY** | **COST** | **EFFICACY** | **ICER (vs BASE CASE)** |
| RR\_response\_ADALIMUMAB | 0.56683 | ADALIMUMAB | 49,651 € | 4.833 QALY | 47,498 €/QALY |
| RR\_response\_ADALIMUMAB | 0.56683 | GOLIMUMAB | 65,378 € | 5.071 QALY | 42,614 €/QALY |
| RR\_response\_ADALIMUMAB | 0.56683 | INFLIXIMAB | 103,803 € | 5.973 QALY | --- |
| RR\_response\_ADALIMUMAB | 0.56683 | VEDOLIZUMAB | 146,985 € | 6.000 QALY | 1,551,649 €/QALY |
| RR\_response\_ADALIMUMAB | 0.63768 | ADALIMUMAB | 55,681 € | 4.940 QALY | 46,591 €/QALY |
| RR\_response\_ADALIMUMAB | 0.63768 | GOLIMUMAB | 65,378 € | 5.071 QALY | 42,614 €/QALY |
| RR\_response\_ADALIMUMAB | 0.63768 | INFLIXIMAB | 103,803 € | 5.973 QALY | --- |
| RR\_response\_ADALIMUMAB | 0.63768 | VEDOLIZUMAB | 146,985 € | 6.000 QALY | 1,551,649 €/QALY |
| RR\_response\_ADALIMUMAB | 0.70853 | ADALIMUMAB | 62,767 € | 5.070 QALY | 45,450 €/QALY |
| RR\_response\_ADALIMUMAB | 0.70853 | GOLIMUMAB | 65,378 € | 5.071 QALY | 42,614 €/QALY |
| RR\_response\_ADALIMUMAB | 0.70853 | INFLIXIMAB | 103,803 € | 5.973 QALY | --- |
| RR\_response\_ADALIMUMAB | 0.70853 | VEDOLIZUMAB | 146,985 € | 6.000 QALY | 1,551,649 €/QALY |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| RR\_response\_ADALIMUMAB | 0.77939 | GOLIMUMAB | 65,378 € | 5.071 QALY | 42,614 €/QALY |
| RR\_response\_ADALIMUMAB | 0.77939 | ADALIMUMAB | 70,540 € | 5.217 QALY | 44,039 €/QALY |
| RR\_response\_ADALIMUMAB | 0.77939 | INFLIXIMAB | 103,803 € | 5.973 QALY | --- |
| RR\_response\_ADALIMUMAB | 0.77939 | VEDOLIZUMAB | 146,985 € | 6.000 QALY | 1,551,649 €/QALY |
| RR\_response\_ADALIMUMAB | 0.85024 | GOLIMUMAB | 65,378 € | 5.071 QALY | 42,614 €/QALY |
| RR\_response\_ADALIMUMAB | 0.85024 | ADALIMUMAB | 78,487 € | 5.373 QALY | 42,240 €/QALY |
| RR\_response\_ADALIMUMAB | 0.85024 | INFLIXIMAB | 103,803 € | 5.973 QALY | --- |
| RR\_response\_ADALIMUMAB | 0.85024 | VEDOLIZUMAB | 146,985 € | 6.000 QALY | 1,551,649 €/QALY |
| **VARIABLE NAME** | **VARIABLE VALUE** | **STRATEGY** | **COST** | **EFFICACY** | **ICER (vs BASE CASE)** |
| RR\_response\_GOLIMUMAB | 0.55326 | GOLIMUMAB | 51,975 € | 4.837 QALY | 45,623 €/QALY |
| RR\_response\_GOLIMUMAB | 0.55326 | ADALIMUMAB | 62,767 € | 5.070 QALY | 45,450 €/QALY |
| RR\_response\_GOLIMUMAB | 0.55326 | INFLIXIMAB | 103,803 € | 5.973 QALY | --- |
| RR\_response\_GOLIMUMAB | 0.55326 | VEDOLIZUMAB | 146,985 € | 6.000 QALY | 1,551,649 €/QALY |
| RR\_response\_GOLIMUMAB | 0.62242 | GOLIMUMAB | 58,100 € | 4.942 QALY | 44,352 €/QALY |
| RR\_response\_GOLIMUMAB | 0.62242 | ADALIMUMAB | 62,767 € | 5.070 QALY | 45,450 €/QALY |
| RR\_response\_GOLIMUMAB | 0.62242 | INFLIXIMAB | 103,803 € | 5.973 QALY | --- |
| RR\_response\_GOLIMUMAB | 0.62242 | VEDOLIZUMAB | 146,985 € | 6.000 QALY | 1,551,649 €/QALY |
| RR\_response\_GOLIMUMAB | 0.69157 | ADALIMUMAB | 62,767 € | 5.070 QALY | 45,450 €/QALY |
| RR\_response\_GOLIMUMAB | 0.69157 | GOLIMUMAB | 65,378 € | 5.071 QALY | 42,614 €/QALY |
| RR\_response\_GOLIMUMAB | 0.69157 | INFLIXIMAB | 103,803 € | 5.973 QALY | --- |
| RR\_response\_GOLIMUMAB | 0.69157 | VEDOLIZUMAB | 146,985 € | 6.000 QALY | 1,551,649 €/QALY |
| RR\_response\_GOLIMUMAB | 0.76073 | ADALIMUMAB | 62,767 € | 5.070 QALY | 45,450 €/QALY |
| RR\_response\_GOLIMUMAB | 0.76073 | GOLIMUMAB | 73,493 € | 5.219 QALY | 40,221 €/QALY |
| RR\_response\_GOLIMUMAB | 0.76073 | INFLIXIMAB | 103,803 € | 5.973 QALY | --- |
| RR\_response\_GOLIMUMAB | 0.76073 | VEDOLIZUMAB | 146,985 € | 6.000 QALY | 1,551,649 €/QALY |
| RR\_response\_GOLIMUMAB | 0.82989 | ADALIMUMAB | 62,767 € | 5.070 QALY | 45,450 €/QALY |
| RR\_response\_GOLIMUMAB | 0.82989 | GOLIMUMAB | 81,950 € | 5.378 QALY | 36,764 €/QALY |
| RR\_response\_GOLIMUMAB | 0.82989 | INFLIXIMAB | 103,803 € | 5.973 QALY | --- |
| RR\_response\_GOLIMUMAB | 0.82989 | VEDOLIZUMAB | 146,985 € | 6.000 QALY | 1,551,649 €/QALY |
| **VARIABLE NAME** | **VARIABLE VALUE** | **STRATEGY** | **COST** | **EFFICACY** | **ICER (vs BASE CASE)** |
| RR\_response\_VEDOLIZUMAB | 0.8 | ADALIMUMAB | 62,767 € | 5.070 QALY | 45,450 €/QALY |
| RR\_response\_VEDOLIZUMAB | 0.8 | GOLIMUMAB | 65,378 € | 5.071 QALY | 42,614 €/QALY |
| RR\_response\_VEDOLIZUMAB | 0.8 | INFLIXIMAB | 103,803 € | 5.973 QALY | --- |
| RR\_response\_VEDOLIZUMAB | 0.8 | VEDOLIZUMAB | 108,840 € | 5.469 QALY | -10,010 €/QALY |
| RR\_response\_VEDOLIZUMAB | 0.9 | ADALIMUMAB | 62,767 € | 5.070 QALY | 45,450 €/QALY |
| RR\_response\_VEDOLIZUMAB | 0.9 | GOLIMUMAB | 65,378 € | 5.071 QALY | 42,614 €/QALY |
| RR\_response\_VEDOLIZUMAB | 0.9 | INFLIXIMAB | 103,803 € | 5.973 QALY | --- |
| RR\_response\_VEDOLIZUMAB | 0.9 | VEDOLIZUMAB | 128,879 € | 5.745 QALY | -110,364 €/QALY |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| RR\_response\_VEDOLIZUMAB | 1 | ADALIMUMAB | 62,767 € | 5.070 QALY | 45,450 €/QALY |
| RR\_response\_VEDOLIZUMAB | 1 | GOLIMUMAB | 65,378 € | 5.071 QALY | 42,614 €/QALY |
| RR\_response\_VEDOLIZUMAB | 1 | INFLIXIMAB | 103,803 € | 5.973 QALY | --- |
| RR\_response\_VEDOLIZUMAB | 1 | VEDOLIZUMAB | 146,985 € | 6.000 QALY | 1,551,649 €/QALY |
| RR\_response\_VEDOLIZUMAB | 1.1 | ADALIMUMAB | 62,767 € | 5.070 QALY | 45,450 €/QALY |
| RR\_response\_VEDOLIZUMAB | 1.1 | GOLIMUMAB | 65,378 € | 5.071 QALY | 42,614 €/QALY |
| RR\_response\_VEDOLIZUMAB | 1.1 | INFLIXIMAB | 103,803 € | 5.973 QALY | --- |
| RR\_response\_VEDOLIZUMAB | 1.1 | VEDOLIZUMAB | 161,890 € | 6.214 QALY | 240,785 €/QALY |
| RR\_response\_VEDOLIZUMAB | 1.2 | ADALIMUMAB | 62,767 € | 5.070 QALY | 45,450 €/QALY |
| RR\_response\_VEDOLIZUMAB | 1.2 | GOLIMUMAB | 65,378 € | 5.071 QALY | 42,614 €/QALY |
| RR\_response\_VEDOLIZUMAB | 1.2 | INFLIXIMAB | 103,803 € | 5.973 QALY | --- |
| RR\_response\_VEDOLIZUMAB | 1.2 | VEDOLIZUMAB | 173,356 € | 6.380 QALY | 170,765 €/QALY |
| **VARIABLE NAME** | **VARIABLE VALUE** | **STRATEGY** | **COST** | **EFFICACY** | **ICER (vs BASE CASE)** |
| Acquisition cost\_ ADALIMUMAB | 395.68599 | ADALIMUMAB | 55,863 € | 5.070 QALY | 53,096 €/QALY |
| Acquisition cost\_ ADALIMUMAB | 395.68599 | GOLIMUMAB | 65,378 € | 5.071 QALY | 42,614 €/QALY |
| Acquisition cost\_ ADALIMUMAB | 395.68599 | INFLIXIMAB | 103,803 € | 5.973 QALY | --- |
| Acquisition cost\_ ADALIMUMAB | 395.68599 | VEDOLIZUMAB | 146,985 € | 6.000 QALY | 1,551,649 €/QALY |
| Acquisition cost\_ ADALIMUMAB | 420.41637 | ADALIMUMAB | 57,589 € | 5.070 QALY | 51,185 €/QALY |
| Acquisition cost\_ ADALIMUMAB | 420.41637 | GOLIMUMAB | 65,378 € | 5.071 QALY | 42,614 €/QALY |
| Acquisition cost\_ ADALIMUMAB | 420.41637 | INFLIXIMAB | 103,803 € | 5.973 QALY | --- |
| Acquisition cost\_ ADALIMUMAB | 420.41637 | VEDOLIZUMAB | 146,985 € | 6.000 QALY | 1,551,649 €/QALY |
| Acquisition cost\_ ADALIMUMAB | 445.14674 | ADALIMUMAB | 59,315 € | 5.070 QALY | 49,273 €/QALY |
| Acquisition cost\_ ADALIMUMAB | 445.14674 | GOLIMUMAB | 65,378 € | 5.071 QALY | 42,614 €/QALY |
| Acquisition cost\_ ADALIMUMAB | 445.14674 | INFLIXIMAB | 103,803 € | 5.973 QALY | --- |
| Acquisition cost\_ ADALIMUMAB | 445.14674 | VEDOLIZUMAB | 146,985 € | 6.000 QALY | 1,551,649 €/QALY |
| Acquisition cost\_ ADALIMUMAB | 469.87712 | ADALIMUMAB | 61,041 € | 5.070 QALY | 47,361 €/QALY |
| Acquisition cost\_ ADALIMUMAB | 469.87712 | GOLIMUMAB | 65,378 € | 5.071 QALY | 42,614 €/QALY |
| Acquisition cost\_ ADALIMUMAB | 469.87712 | INFLIXIMAB | 103,803 € | 5.973 QALY | --- |
| Acquisition cost\_ ADALIMUMAB | 469.87712 | VEDOLIZUMAB | 146,985 € | 6.000 QALY | 1,551,649 €/QALY |
| Acquisition cost\_ ADALIMUMAB | 494.60749 | ADALIMUMAB | 62,767 € | 5.070 QALY | 45,450 €/QALY |
| Acquisition cost\_ ADALIMUMAB | 494.60749 | GOLIMUMAB | 65,378 € | 5.071 QALY | 42,614 €/QALY |
| Acquisition cost\_ ADALIMUMAB | 494.60749 | INFLIXIMAB | 103,803 € | 5.973 QALY | --- |
| Acquisition cost\_ ADALIMUMAB | 494.60749 | VEDOLIZUMAB | 146,985 € | 6.000 QALY | 1,551,649 €/QALY |
| **VARIABLE NAME** | **VARIABLE VALUE** | **STRATEGY** | **COST** | **EFFICACY** | **ICER (vs BASE CASE)** |
| Acquisition cost\_ GOLIMUMAB 100 MG | 1719.2864 | ADALIMUMAB | 62,767 € | 5.070 QALY | 45,450 €/QALY |
| Acquisition cost\_ GOLIMUMAB 100 MG | 1719.2864 | GOLIMUMAB | 64,733 € | 5.071 QALY | 43,329 €/QALY |
| Acquisition cost\_ GOLIMUMAB 100 MG | 1719.2864 | INFLIXIMAB | 103,803 € | 5.973 QALY | --- |
| Acquisition cost\_ GOLIMUMAB 100 MG | 1719.2864 | VEDOLIZUMAB | 146,985 € | 6.000 QALY | 1,551,649 €/QALY |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Acquisition cost\_ GOLIMUMAB 100 MG | 1826.7418 | ADALIMUMAB | 62,767 € | 5.070 QALY | 45,450 €/QALY |
| Acquisition cost\_ GOLIMUMAB 100 MG | 1826.7418 | GOLIMUMAB | 64,895 € | 5.071 QALY | 43,151 €/QALY |
| Acquisition cost\_ GOLIMUMAB 100 MG | 1826.7418 | INFLIXIMAB | 103,803 € | 5.973 QALY | --- |
| Acquisition cost\_ GOLIMUMAB 100 MG | 1826.7418 | VEDOLIZUMAB | 146,985 € | 6.000 QALY | 1,551,649 €/QALY |
| Acquisition cost\_ GOLIMUMAB 100 MG | 1934.1972 | ADALIMUMAB | 62,767 € | 5.070 QALY | 45,450 €/QALY |
| Acquisition cost\_ GOLIMUMAB 100 MG | 1934.1972 | GOLIMUMAB | 65,056 € | 5.071 QALY | 42,972 €/QALY |
| Acquisition cost\_ GOLIMUMAB 100 MG | 1934.1972 | INFLIXIMAB | 103,803 € | 5.973 QALY | --- |
| Acquisition cost\_ GOLIMUMAB 100 MG | 1934.1972 | VEDOLIZUMAB | 146,985 € | 6.000 QALY | 1,551,649 €/QALY |
| Acquisition cost\_ GOLIMUMAB 100 MG | 2041.6526 | ADALIMUMAB | 62,767 € | 5.070 QALY | 45,450 €/QALY |
| Acquisition cost\_ GOLIMUMAB 100 MG | 2041.6526 | GOLIMUMAB | 65,217 € | 5.071 QALY | 42,793 €/QALY |
| Acquisition cost\_ GOLIMUMAB 100 MG | 2041.6526 | INFLIXIMAB | 103,803 € | 5.973 QALY | --- |
| Acquisition cost\_ GOLIMUMAB 100 MG | 2041.6526 | VEDOLIZUMAB | 146,985 € | 6.000 QALY | 1,551,649 €/QALY |
| Acquisition cost\_ GOLIMUMAB 100 MG | 2149.108 | ADALIMUMAB | 62,767 € | 5.070 QALY | 45,450 €/QALY |
| Acquisition cost\_ GOLIMUMAB 100 MG | 2149.108 | GOLIMUMAB | 65,378 € | 5.071 QALY | 42,614 €/QALY |
| Acquisition cost\_ GOLIMUMAB 100 MG | 2149.108 | INFLIXIMAB | 103,803 € | 5.973 QALY | --- |
| Acquisition cost\_ GOLIMUMAB 100 MG | 2149.108 | VEDOLIZUMAB | 146,985 € | 6.000 QALY | 1,551,649 €/QALY |
| **VARIABLE NAME** | **VARIABLE VALUE** | **STRATEGY** | **COST** | **EFFICACY** | **ICER (vs BASE CASE)** |
| Acquisition cost\_ GOLIMUMAB 50 MG | 859.6432 | GOLIMUMAB | 58,594 € | 5.071 QALY | 50,139 €/QALY |
| Acquisition cost\_ GOLIMUMAB 50 MG | 859.6432 | ADALIMUMAB | 62,767 € | 5.070 QALY | 45,450 €/QALY |
| Acquisition cost\_ GOLIMUMAB 50 MG | 859.6432 | INFLIXIMAB | 103,803 € | 5.973 QALY | --- |
| Acquisition cost\_ GOLIMUMAB 50 MG | 859.6432 | VEDOLIZUMAB | 146,985 € | 6.000 QALY | 1,551,649 €/QALY |
| Acquisition cost\_ GOLIMUMAB 50 MG | 913.3709 | GOLIMUMAB | 60,290 € | 5.071 QALY | 48,258 €/QALY |
| Acquisition cost\_ GOLIMUMAB 50 MG | 913.3709 | ADALIMUMAB | 62,767 € | 5.070 QALY | 45,450 €/QALY |
| Acquisition cost\_ GOLIMUMAB 50 MG | 913.3709 | INFLIXIMAB | 103,803 € | 5.973 QALY | --- |
| Acquisition cost\_ GOLIMUMAB 50 MG | 913.3709 | VEDOLIZUMAB | 146,985 € | 6.000 QALY | 1,551,649 €/QALY |
| Acquisition cost\_ GOLIMUMAB 50 MG | 967.0986 | GOLIMUMAB | 61,986 € | 5.071 QALY | 46,377 €/QALY |
| Acquisition cost\_ GOLIMUMAB 50 MG | 967.0986 | ADALIMUMAB | 62,767 € | 5.070 QALY | 45,450 €/QALY |
| Acquisition cost\_ GOLIMUMAB 50 MG | 967.0986 | INFLIXIMAB | 103,803 € | 5.973 QALY | --- |
| Acquisition cost\_ GOLIMUMAB 50 MG | 967.0986 | VEDOLIZUMAB | 146,985 € | 6.000 QALY | 1,551,649 €/QALY |
| Acquisition cost\_ GOLIMUMAB 50 MG | 1020.8263 | ADALIMUMAB | 62,767 € | 5.070 QALY | 45,450 €/QALY |
| Acquisition cost\_ GOLIMUMAB 50 MG | 1020.8263 | GOLIMUMAB | 63,682 € | 5.071 QALY | 44,495 €/QALY |
| Acquisition cost\_ GOLIMUMAB 50 MG | 1020.8263 | INFLIXIMAB | 103,803 € | 5.973 QALY | --- |
| Acquisition cost\_ GOLIMUMAB 50 MG | 1020.8263 | VEDOLIZUMAB | 146,985 € | 6.000 QALY | 1,551,649 €/QALY |
| Acquisition cost\_ GOLIMUMAB 50 MG | 1074.554 | ADALIMUMAB | 62,767 € | 5.070 QALY | 45,450 €/QALY |
| Acquisition cost\_ GOLIMUMAB 50 MG | 1074.554 | GOLIMUMAB | 65,378 € | 5.071 QALY | 42,614 €/QALY |
| Acquisition cost\_ GOLIMUMAB 50 MG | 1074.554 | INFLIXIMAB | 103,803 € | 5.973 QALY | --- |
| Acquisition cost\_ GOLIMUMAB 50 MG | 1074.554 | VEDOLIZUMAB | 146,985 € | 6.000 QALY | 1,551,649 €/QALY |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **VARIABLE NAME** | **VARIABLE VALUE** | **STRATEGY** | **COST** | **EFFICACY** | **ICER (vs BASE CASE)** |
| Acquisition cost\_ INFLIXIMAB | 4.46185 | ADALIMUMAB | 62,767 € | 5.070 QALY | 29,125 €/QALY |
| Acquisition cost\_ INFLIXIMAB | 4.46185 | GOLIMUMAB | 65,378 € | 5.071 QALY | 26,268 €/QALY |
| Acquisition cost\_ INFLIXIMAB | 4.46185 | INFLIXIMAB | 89,064 € | 5.973 QALY | --- |
| Acquisition cost\_ INFLIXIMAB | 4.46185 | VEDOLIZUMAB | 146,985 € | 6.000 QALY | 2,081,255 €/QALY |
| Acquisition cost\_ INFLIXIMAB | 4.74072 | ADALIMUMAB | 62,767 € | 5.070 QALY | 33,207 €/QALY |
| Acquisition cost\_ INFLIXIMAB | 4.74072 | GOLIMUMAB | 65,378 € | 5.071 QALY | 30,355 €/QALY |
| Acquisition cost\_ INFLIXIMAB | 4.74072 | INFLIXIMAB | 92,749 € | 5.973 QALY | --- |
| Acquisition cost\_ INFLIXIMAB | 4.74072 | VEDOLIZUMAB | 146,985 € | 6.000 QALY | 1,948,854 €/QALY |
| Acquisition cost\_ INFLIXIMAB | 5.01958 | ADALIMUMAB | 62,767 € | 5.070 QALY | 37,288 €/QALY |
| Acquisition cost\_ INFLIXIMAB | 5.01958 | GOLIMUMAB | 65,378 € | 5.071 QALY | 34,441 €/QALY |
| Acquisition cost\_ INFLIXIMAB | 5.01958 | INFLIXIMAB | 96,433 € | 5.973 QALY | --- |
| Acquisition cost\_ INFLIXIMAB | 5.01958 | VEDOLIZUMAB | 146,985 € | 6.000 QALY | 1,816,452 €/QALY |
| Acquisition cost\_ INFLIXIMAB | 5.29845 | ADALIMUMAB | 62,767 € | 5.070 QALY | 41,369 €/QALY |
| Acquisition cost\_ INFLIXIMAB | 5.29845 | GOLIMUMAB | 65,378 € | 5.071 QALY | 38,528 €/QALY |
| Acquisition cost\_ INFLIXIMAB | 5.29845 | INFLIXIMAB | 100,118 € | 5.973 QALY | --- |
| Acquisition cost\_ INFLIXIMAB | 5.29845 | VEDOLIZUMAB | 146,985 € | 6.000 QALY | 1,684,051 €/QALY |
| Acquisition cost\_ INFLIXIMAB | 5.57731 | ADALIMUMAB | 62,767 € | 5.070 QALY | 45,450 €/QALY |
| Acquisition cost\_ INFLIXIMAB | 5.57731 | GOLIMUMAB | 65,378 € | 5.071 QALY | 42,614 €/QALY |
| Acquisition cost\_ INFLIXIMAB | 5.57731 | INFLIXIMAB | 103,803 € | 5.973 QALY | --- |
| Acquisition cost\_ INFLIXIMAB | 5.57731 | VEDOLIZUMAB | 146,985 € | 6.000 QALY | 1,551,649 €/QALY |
| **VARIABLE NAME** | **VARIABLE VALUE** | **STRATEGY** | **COST** | **EFFICACY** | **ICER (vs BASE CASE)** |
| Acquisition cost\_ VEDOLIZUMAB | 2667.4336 | ADALIMUMAB | 62,767 € | 5.070 QALY | 45,450 €/QALY |
| Acquisition cost\_ VEDOLIZUMAB | 2667.4336 | GOLIMUMAB | 65,378 € | 5.071 QALY | 42,614 €/QALY |
| Acquisition cost\_ VEDOLIZUMAB | 2667.4336 | INFLIXIMAB | 103,803 € | 5.973 QALY | --- |
| Acquisition cost\_ VEDOLIZUMAB | 2667.4336 | VEDOLIZUMAB | 123,858 € | 6.000 QALY | 720,637 €/QALY |
| Acquisition cost\_ VEDOLIZUMAB | 2834.1482 | ADALIMUMAB | 62,767 € | 5.070 QALY | 45,450 €/QALY |
| Acquisition cost\_ VEDOLIZUMAB | 2834.1482 | GOLIMUMAB | 65,378 € | 5.071 QALY | 42,614 €/QALY |
| Acquisition cost\_ VEDOLIZUMAB | 2834.1482 | INFLIXIMAB | 103,803 € | 5.973 QALY | --- |
| Acquisition cost\_ VEDOLIZUMAB | 2834.1482 | VEDOLIZUMAB | 129,640 € | 6.000 QALY | 928,390 €/QALY |
| Acquisition cost\_ VEDOLIZUMAB | 3000.8628 | ADALIMUMAB | 62,767 € | 5.070 QALY | 45,450 €/QALY |
| Acquisition cost\_ VEDOLIZUMAB | 3000.8628 | GOLIMUMAB | 65,378 € | 5.071 QALY | 42,614 €/QALY |
| Acquisition cost\_ VEDOLIZUMAB | 3000.8628 | INFLIXIMAB | 103,803 € | 5.973 QALY | --- |
| Acquisition cost\_ VEDOLIZUMAB | 3000.8628 | VEDOLIZUMAB | 135,422 € | 6.000 QALY | 1,136,143 €/QALY |
| Acquisition cost\_ VEDOLIZUMAB | 3167.5774 | ADALIMUMAB | 62,767 € | 5.070 QALY | 45,450 €/QALY |
| Acquisition cost\_ VEDOLIZUMAB | 3167.5774 | GOLIMUMAB | 65,378 € | 5.071 QALY | 42,614 €/QALY |
| Acquisition cost\_ VEDOLIZUMAB | 3167.5774 | INFLIXIMAB | 103,803 € | 5.973 QALY | --- |
| Acquisition cost\_ VEDOLIZUMAB | 3167.5774 | VEDOLIZUMAB | 141,203 € | 6.000 QALY | 1,343,896 €/QALY |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Acquisition cost\_ VEDOLIZUMAB | 3334.292 | ADALIMUMAB | 62,767 € | 5.070 QALY | 45,450 €/QALY |
| Acquisition cost\_ VEDOLIZUMAB | 3334.292 | GOLIMUMAB | 65,378 € | 5.071 QALY | 42,614 €/QALY |
| Acquisition cost\_ VEDOLIZUMAB | 3334.292 | INFLIXIMAB | 103,803 € | 5.973 QALY | --- |
| Acquisition cost\_ VEDOLIZUMAB | 3334.292 | VEDOLIZUMAB | 146,985 € | 6.000 QALY | 1,551,649 €/QALY |
| **VARIABLE NAME** | **VARIABLE VALUE** | **STRATEGY** | **COST** | **EFFICACY** | **ICER (vs BASE CASE)** |
| Acquisition cost\_ INFLECTRA | 3.65872 | ADALIMUMAB | 62,767 € | 5.070 QALY | 17,372 €/QALY |
| Acquisition cost\_ INFLECTRA | 3.65872 | GOLIMUMAB | 57,949 € | 5.071 QALY | 22,738 €/QALY |
| Acquisition cost\_ INFLECTRA | 3.65872 | INFLIXIMAB | 78,452 € | 5.973 QALY | --- |
| Acquisition cost\_ INFLECTRA | 3.65872 | VEDOLIZUMAB | 146,985 € | 6.000 QALY | 2,462,571 €/QALY |
| Acquisition cost\_ INFLECTRA | 3.88739 | ADALIMUMAB | 62,767 € | 5.070 QALY | 20,718 €/QALY |
| Acquisition cost\_ INFLECTRA | 3.88739 | GOLIMUMAB | 57,949 € | 5.071 QALY | 26,089 €/QALY |
| Acquisition cost\_ INFLECTRA | 3.88739 | INFLIXIMAB | 81,473 € | 5.973 QALY | --- |
| Acquisition cost\_ INFLECTRA | 3.88739 | VEDOLIZUMAB | 146,985 € | 6.000 QALY | 2,354,001 €/QALY |
| Acquisition cost\_ INFLECTRA | 4.11606 | ADALIMUMAB | 62,767 € | 5.070 QALY | 24,065 €/QALY |
| Acquisition cost\_ INFLECTRA | 4.11606 | GOLIMUMAB | 57,949 € | 5.071 QALY | 29,440 €/QALY |
| Acquisition cost\_ INFLECTRA | 4.11606 | INFLIXIMAB | 84,495 € | 5.973 QALY | --- |
| Acquisition cost\_ INFLECTRA | 4.11606 | VEDOLIZUMAB | 146,985 € | 6.000 QALY | 2,245,432 €/QALY |
| Acquisition cost\_ INFLECTRA | 4.34473 | ADALIMUMAB | 62,767 € | 5.070 QALY | 27,411 €/QALY |
| Acquisition cost\_ INFLECTRA | 4.34473 | GOLIMUMAB | 57,949 € | 5.071 QALY | 32,791 €/QALY |
| Acquisition cost\_ INFLECTRA | 4.34473 | INFLIXIMAB | 87,516 € | 5.973 QALY | --- |
| Acquisition cost\_ INFLECTRA | 4.34473 | VEDOLIZUMAB | 146,985 € | 6.000 QALY | 2,136,862 €/QALY |
| Acquisition cost\_ INFLECTRA | 4.5734 | ADALIMUMAB | 62,767 € | 5.070 QALY | 30,758 €/QALY |
| Acquisition cost\_ INFLECTRA | 4.5734 | GOLIMUMAB | 57,949 € | 5.071 QALY | 36,142 €/QALY |
| Acquisition cost\_ INFLECTRA | 4.5734 | INFLIXIMAB | 90,538 € | 5.973 QALY | --- |
| Acquisition cost\_ INFLECTRA | 4.5734 | VEDOLIZUMAB | 146,985 € | 6.000 QALY | 2,028,293 €/QALY |
| **VARIABLE NAME** | **VARIABLE VALUE** | **STRATEGY** | **COST** | **EFFICACY** | **ICER (vs BASE CASE)** |
| SURGERY utility | 0.544 | ADALIMUMAB | 62,767 € | 5.056 QALY | 45,175 €/QALY |
| SURGERY utility | 0.544 | GOLIMUMAB | 65,378 € | 5.057 QALY | 42,348 €/QALY |
| SURGERY utility | 0.544 | INFLIXIMAB | 103,803 € | 5.965 QALY | --- |
| SURGERY utility | 0.544 | VEDOLIZUMAB | 146,985 € | 5.993 QALY | 1,551,092 €/QALY |
| SURGERY utility | 0.612 | ADALIMUMAB | 62,767 € | 5.063 QALY | 45,312 €/QALY |
| SURGERY utility | 0.612 | GOLIMUMAB | 65,378 € | 5.064 QALY | 42,481 €/QALY |
| SURGERY utility | 0.612 | INFLIXIMAB | 103,803 € | 5.969 QALY | --- |
| SURGERY utility | 0.612 | VEDOLIZUMAB | 146,985 € | 5.997 QALY | 1,551,092 €/QALY |
| SURGERY utility | 0.68 | ADALIMUMAB | 62,767 € | 5.070 QALY | 45,450 €/QALY |
| SURGERY utility | 0.68 | GOLIMUMAB | 65,378 € | 5.071 QALY | 42,614 €/QALY |
| SURGERY utility | 0.68 | INFLIXIMAB | 103,803 € | 5.973 QALY | --- |
| SURGERY utility | 0.68 | VEDOLIZUMAB | 146,985 € | 6.000 QALY | 1,551,649 €/QALY |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| SURGERY utility | 0.748 | ADALIMUMAB | 62,767 € | 5.076 QALY | 45,588 €/QALY |
| SURGERY utility | 0.748 | GOLIMUMAB | 65,378 € | 5.078 QALY | 42,749 €/QALY |
| SURGERY utility | 0.748 | INFLIXIMAB | 103,803 € | 5.977 QALY | --- |
| SURGERY utility | 0.748 | VEDOLIZUMAB | 146,985 € | 6.004 QALY | 1,551,092 €/QALY |
| SURGERY utility | 0.816 | ADALIMUMAB | 62,767 € | 5.083 QALY | 45,728 €/QALY |
| SURGERY utility | 0.816 | GOLIMUMAB | 65,378 € | 5.084 QALY | 42,885 €/QALY |
| SURGERY utility | 0.816 | INFLIXIMAB | 103,803 € | 5.980 QALY | --- |
| SURGERY utility | 0.816 | VEDOLIZUMAB | 146,985 € | 6.008 QALY | 1,551,092 €/QALY |
| **VARIABLE NAME** | **VARIABLE VALUE** | **STRATEGY** | **COST** | **EFFICACY** | **ICER (vs BASE CASE)** |
| SURGERY utility\_COMPLICATION | 0.392 | ADALIMUMAB | 62,767 € | 5.059 QALY | 45,169 €/QALY |
| SURGERY utility\_COMPLICATION | 0.392 | GOLIMUMAB | 65,378 € | 5.060 QALY | 42,336 €/QALY |
| SURGERY utility\_COMPLICATION | 0.392 | INFLIXIMAB | 103,803 € | 5.967 QALY | --- |
| SURGERY utility\_COMPLICATION | 0.392 | VEDOLIZUMAB | 146,985 € | 5.995 QALY | 1,551,092 €/QALY |
| SURGERY utility\_COMPLICATION | 0.441 | ADALIMUMAB | 62,767 € | 5.064 QALY | 45,309 €/QALY |
| SURGERY utility\_COMPLICATION | 0.441 | GOLIMUMAB | 65,378 € | 5.065 QALY | 42,475 €/QALY |
| SURGERY utility\_COMPLICATION | 0.441 | INFLIXIMAB | 103,803 € | 5.970 QALY | --- |
| SURGERY utility\_COMPLICATION | 0.441 | VEDOLIZUMAB | 146,985 € | 5.998 QALY | 1,551,092 €/QALY |
| SURGERY utility\_COMPLICATION | 0.49 | ADALIMUMAB | 62,767 € | 5.070 QALY | 45,449 €/QALY |
| SURGERY utility\_COMPLICATION | 0.49 | GOLIMUMAB | 65,378 € | 5.071 QALY | 42,614 €/QALY |
| SURGERY utility\_COMPLICATION | 0.49 | INFLIXIMAB | 103,803 € | 5.973 QALY | --- |
| SURGERY utility\_COMPLICATION | 0.49 | VEDOLIZUMAB | 146,985 € | 6.000 QALY | 1,551,649 €/QALY |
| SURGERY utility\_COMPLICATION | 0.539 | ADALIMUMAB | 62,767 € | 5.075 QALY | 45,592 €/QALY |
| SURGERY utility\_COMPLICATION | 0.539 | GOLIMUMAB | 65,378 € | 5.076 QALY | 42,756 €/QALY |
| SURGERY utility\_COMPLICATION | 0.539 | INFLIXIMAB | 103,803 € | 5.975 QALY | --- |
| SURGERY utility\_COMPLICATION | 0.539 | VEDOLIZUMAB | 146,985 € | 6.003 QALY | 1,551,092 €/QALY |
| SURGERY utility\_COMPLICATION | 0.588 | ADALIMUMAB | 62,767 € | 5.080 QALY | 45,734 €/QALY |
| SURGERY utility\_COMPLICATION | 0.588 | GOLIMUMAB | 65,378 € | 5.082 QALY | 42,897 €/QALY |
| SURGERY utility\_COMPLICATION | 0.588 | INFLIXIMAB | 103,803 € | 5.978 QALY | --- |
| SURGERY utility\_COMPLICATION | 0.588 | VEDOLIZUMAB | 146,985 € | 6.006 QALY | 1,551,092 €/QALY |
| **VARIABLE NAME** | **VARIABLE VALUE** | **STRATEGY** | **COST** | **EFFICACY** | **ICER (vs BASE CASE)** |
| SURGERY utility\_REMISSION | 0.544 | ADALIMUMAB | 62,767 € | 4.636 QALY | 36,391 €/QALY |
| SURGERY utility\_REMISSION | 0.544 | GOLIMUMAB | 65,378 € | 4.625 QALY | 33,732 €/QALY |
| SURGERY utility\_REMISSION | 0.544 | INFLIXIMAB | 103,803 € | 5.764 QALY | --- |
| SURGERY utility\_REMISSION | 0.544 | VEDOLIZUMAB | 146,985 € | 5.792 QALY | 1,551,092 €/QALY |
| SURGERY utility\_REMISSION | 0.612 | ADALIMUMAB | 62,767 € | 4.853 QALY | 40,419 €/QALY |
| SURGERY utility\_REMISSION | 0.612 | GOLIMUMAB | 65,378 € | 4.848 QALY | 37,656 €/QALY |
| SURGERY utility\_REMISSION | 0.612 | INFLIXIMAB | 103,803 € | 5.868 QALY | --- |
| SURGERY utility\_REMISSION | 0.612 | VEDOLIZUMAB | 146,985 € | 5.896 QALY | 1,551,092 €/QALY |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| SURGERY utility\_REMISSION | 0.68 | ADALIMUMAB | 62,767 € | 5.070 QALY | 45,449 €/QALY |
| SURGERY utility\_REMISSION | 0.68 | GOLIMUMAB | 65,378 € | 5.071 QALY | 42,614 €/QALY |
| SURGERY utility\_REMISSION | 0.68 | INFLIXIMAB | 103,803 € | 5.973 QALY | --- |
| SURGERY utility\_REMISSION | 0.68 | VEDOLIZUMAB | 146,985 € | 6.000 QALY | 1,551,649 €/QALY |
| SURGERY utility\_REMISSION | 0.748 | ADALIMUMAB | 62,767 € | 5.287 QALY | 51,910 €/QALY |
| SURGERY utility\_REMISSION | 0.748 | GOLIMUMAB | 65,378 € | 5.294 QALY | 49,075 €/QALY |
| SURGERY utility\_REMISSION | 0.748 | INFLIXIMAB | 103,803 € | 6.077 QALY | --- |
| SURGERY utility\_REMISSION | 0.748 | VEDOLIZUMAB | 146,985 € | 6.105 QALY | 1,551,092 €/QALY |
| SURGERY utility\_REMISSION | 0.816 | ADALIMUMAB | 62,767 € | 5.503 QALY | 60,510 €/QALY |
| SURGERY utility\_REMISSION | 0.816 | GOLIMUMAB | 65,378 € | 5.517 QALY | 57,846 €/QALY |
| SURGERY utility\_REMISSION | 0.816 | INFLIXIMAB | 103,803 € | 6.181 QALY | --- |
| SURGERY utility\_REMISSION | 0.816 | VEDOLIZUMAB | 146,985 € | 6.209 QALY | 1,551,092 €/QALY |
| **VARIABLE NAME** | **VARIABLE VALUE** | **STRATEGY** | **COST** | **EFFICACY** | **ICER (vs BASE CASE)** |
| ACTIVE DISEASE\_utility | 0.37 | ADALIMUMAB | 62,767 € | 4.997 QALY | 43,831 €/QALY |
| ACTIVE DISEASE\_utility | 0.37 | GOLIMUMAB | 65,378 € | 4.997 QALY | 41,044 €/QALY |
| ACTIVE DISEASE\_utility | 0.37 | INFLIXIMAB | 103,803 € | 5.933 QALY | --- |
| ACTIVE DISEASE\_utility | 0.37 | VEDOLIZUMAB | 146,985 € | 5.961 QALY | 1,575,425 €/QALY |
| ACTIVE DISEASE\_utility | 0.39025 | ADALIMUMAB | 62,767 € | 5.034 QALY | 44,636 €/QALY |
| ACTIVE DISEASE\_utility | 0.39025 | GOLIMUMAB | 65,378 € | 5.035 QALY | 41,824 €/QALY |
| ACTIVE DISEASE\_utility | 0.39025 | INFLIXIMAB | 103,803 € | 5.953 QALY | --- |
| ACTIVE DISEASE\_utility | 0.39025 | VEDOLIZUMAB | 146,985 € | 5.981 QALY | 1,562,881 €/QALY |
| ACTIVE DISEASE\_utility | 0.4105 | ADALIMUMAB | 62,767 € | 5.071 QALY | 45,470 €/QALY |
| ACTIVE DISEASE\_utility | 0.4105 | GOLIMUMAB | 65,378 € | 5.072 QALY | 42,635 €/QALY |
| ACTIVE DISEASE\_utility | 0.4105 | INFLIXIMAB | 103,803 € | 5.973 QALY | --- |
| ACTIVE DISEASE\_utility | 0.4105 | VEDOLIZUMAB | 146,985 € | 6.001 QALY | 1,551,092 €/QALY |
| ACTIVE DISEASE\_utility | 0.43075 | ADALIMUMAB | 62,767 € | 5.107 QALY | 46,338 €/QALY |
| ACTIVE DISEASE\_utility | 0.43075 | GOLIMUMAB | 65,378 € | 5.109 QALY | 43,478 €/QALY |
| ACTIVE DISEASE\_utility | 0.43075 | INFLIXIMAB | 103,803 € | 5.993 QALY | --- |
| ACTIVE DISEASE\_utility | 0.43075 | VEDOLIZUMAB | 146,985 € | 6.021 QALY | 1,538,382 €/QALY |
| ACTIVE DISEASE\_utility | 0.451 | ADALIMUMAB | 62,767 € | 5.144 QALY | 47,238 €/QALY |
| ACTIVE DISEASE\_utility | 0.451 | GOLIMUMAB | 65,378 € | 5.147 QALY | 44,355 €/QALY |
| ACTIVE DISEASE\_utility | 0.451 | INFLIXIMAB | 103,803 € | 6.013 QALY | --- |
| ACTIVE DISEASE\_utility | 0.451 | VEDOLIZUMAB | 146,985 € | 6.041 QALY | 1,526,959 €/QALY |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **VARIABLE NAME** | **VARIABLE VALUE** | **STRATEGY** | **COST** | **EFFICACY** | **ICER (vs BASE CASE)** |
| REMISSION\_utility | 0.783 | ADALIMUMAB | 62,767 € | 4.943 QALY | 58,930 €/QALY |
| REMISSION\_utility | 0.783 | GOLIMUMAB | 65,378 € | 4.934 QALY | 54,433 €/QALY |
| REMISSION\_utility | 0.783 | INFLIXIMAB | 103,803 € | 5.640 QALY | --- |
| REMISSION\_utility | 0.783 | VEDOLIZUMAB | 146,985 € | 5.670 QALY | 1,447,616 €/QALY |
| REMISSION\_utility | 0.8265 | ADALIMUMAB | 62,767 € | 5.007 QALY | 51,319 €/QALY |
| REMISSION\_utility | 0.8265 | GOLIMUMAB | 65,378 € | 5.002 QALY | 47,804 €/QALY |
| REMISSION\_utility | 0.8265 | INFLIXIMAB | 103,803 € | 5.806 QALY | --- |
| REMISSION\_utility | 0.8265 | VEDOLIZUMAB | 146,985 € | 5.835 QALY | 1,497,828 €/QALY |
| REMISSION\_utility | 0.87 | ADALIMUMAB | 62,767 € | 5.070 QALY | 45,450 €/QALY |
| REMISSION\_utility | 0.87 | GOLIMUMAB | 65,378 € | 5.071 QALY | 42,614 €/QALY |
| REMISSION\_utility | 0.87 | INFLIXIMAB | 103,803 € | 5.973 QALY | --- |
| REMISSION\_utility | 0.87 | VEDOLIZUMAB | 146,985 € | 6.000 QALY | 1,551,649 €/QALY |
| REMISSION\_utility | 0.9135 | ADALIMUMAB | 62,767 € | 5.133 QALY | 40,785 €/QALY |
| REMISSION\_utility | 0.9135 | GOLIMUMAB | 65,378 € | 5.140 QALY | 38,442 €/QALY |
| REMISSION\_utility | 0.9135 | INFLIXIMAB | 103,803 € | 6.139 QALY | --- |
| REMISSION\_utility | 0.9135 | VEDOLIZUMAB | 146,985 € | 6.166 QALY | 1,608,283 €/QALY |
| REMISSION\_utility | 0.957 | ADALIMUMAB | 62,767 € | 5.196 QALY | 36,989 €/QALY |
| REMISSION\_utility | 0.957 | GOLIMUMAB | 65,378 € | 5.208 QALY | 35,013 €/QALY |
| REMISSION\_utility | 0.957 | INFLIXIMAB | 103,803 € | 6.305 QALY | --- |
| REMISSION\_utility | 0.957 | VEDOLIZUMAB | 146,985 € | 6.331 QALY | 1,670,499 €/QALY |
| **VARIABLE NAME** | **VARIABLE VALUE** | **STRATEGY** | **COST** | **EFFICACY** | **ICER (vs BASE CASE)** |
| RESPONSE\_utility | 0.684 | ADALIMUMAB | 62,767 € | 4.993 QALY | 46,267 €/QALY |
| RESPONSE\_utility | 0.684 | GOLIMUMAB | 65,378 € | 5.014 QALY | 44,337 €/QALY |
| RESPONSE\_utility | 0.684 | INFLIXIMAB | 103,803 € | 5.880 QALY | --- |
| RESPONSE\_utility | 0.684 | VEDOLIZUMAB | 146,985 € | 5.907 QALY | 1,604,697 €/QALY |
| RESPONSE\_utility | 0.722 | ADALIMUMAB | 62,767 € | 5.032 QALY | 45,855 €/QALY |
| RESPONSE\_utility | 0.722 | GOLIMUMAB | 65,378 € | 5.042 QALY | 43,459 €/QALY |
| RESPONSE\_utility | 0.722 | INFLIXIMAB | 103,803 € | 5.926 QALY | --- |
| RESPONSE\_utility | 0.722 | VEDOLIZUMAB | 146,985 € | 5.954 QALY | 1,577,727 €/QALY |
| RESPONSE\_utility | 0.76 | ADALIMUMAB | 62,767 € | 5.070 QALY | 45,450 €/QALY |
| RESPONSE\_utility | 0.76 | GOLIMUMAB | 65,378 € | 5.071 QALY | 42,614 €/QALY |
| RESPONSE\_utility | 0.76 | INFLIXIMAB | 103,803 € | 5.973 QALY | --- |
| RESPONSE\_utility | 0.76 | VEDOLIZUMAB | 146,985 € | 6.000 QALY | 1,551,649 €/QALY |
| RESPONSE\_utility | 0.798 | ADALIMUMAB | 62,767 € | 5.108 QALY | 45,052 €/QALY |
| RESPONSE\_utility | 0.798 | GOLIMUMAB | 65,378 € | 5.100 QALY | 41,803 €/QALY |
| RESPONSE\_utility | 0.798 | INFLIXIMAB | 103,803 € | 6.019 QALY | --- |
| RESPONSE\_utility | 0.798 | VEDOLIZUMAB | 146,985 € | 6.047 QALY | 1,525,879 €/QALY |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| RESPONSE\_utility | 0.836 | ADALIMUMAB | 62,767 € | 5.146 QALY | 44,661 €/QALY |
| RESPONSE\_utility | 0.836 | GOLIMUMAB | 65,378 € | 5.128 QALY | 41,022 €/QALY |
| RESPONSE\_utility | 0.836 | INFLIXIMAB | 103,803 € | 6.065 QALY | --- |
| RESPONSE\_utility | 0.836 | VEDOLIZUMAB | 146,985 € | 6.094 QALY | 1,501,474 €/QALY |
| **VARIABLE NAME** | **VARIABLE VALUE** | **STRATEGY** | **COST** | **EFFICACY** | **ICER (vs BASE CASE)** |
| p\_surgery\_short-term | 0.154 | ADALIMUMAB | 63,208 € | 4.958 QALY | 42,396 €/QALY |
| p\_surgery\_short-term | 0.154 | GOLIMUMAB | 65,845 € | 4.956 QALY | 39,569 €/QALY |
| p\_surgery\_short-term | 0.154 | INFLIXIMAB | 103,919 € | 5.918 QALY | --- |
| p\_surgery\_short-term | 0.154 | VEDOLIZUMAB | 147,102 € | 5.946 QALY | 1,551,092 €/QALY |
| p\_surgery\_short-term | 0.17329 | ADALIMUMAB | 62,977 € | 5.017 QALY | 43,958 €/QALY |
| p\_surgery\_short-term | 0.17329 | GOLIMUMAB | 65,600 € | 5.016 QALY | 41,124 €/QALY |
| p\_surgery\_short-term | 0.17329 | INFLIXIMAB | 103,859 € | 5.947 QALY | --- |
| p\_surgery\_short-term | 0.17329 | VEDOLIZUMAB | 147,041 € | 5.975 QALY | 1,551,092 €/QALY |
| p\_surgery\_short-term | 0.19258 | ADALIMUMAB | 62,768 € | 5.070 QALY | 45,446 €/QALY |
| p\_surgery\_short-term | 0.19258 | GOLIMUMAB | 65,379 € | 5.071 QALY | 42,611 €/QALY |
| p\_surgery\_short-term | 0.19258 | INFLIXIMAB | 103,803 € | 5.973 QALY | --- |
| p\_surgery\_short-term | 0.19258 | VEDOLIZUMAB | 146,985 € | 6.000 QALY | 1,551,092 €/QALY |
| p\_surgery\_short-term | 0.21187 | ADALIMUMAB | 62,578 € | 5.117 QALY | 46,853 €/QALY |
| p\_surgery\_short-term | 0.21187 | GOLIMUMAB | 65,179 € | 5.119 QALY | 44,021 €/QALY |
| p\_surgery\_short-term | 0.21187 | INFLIXIMAB | 103,752 € | 5.996 QALY | --- |
| p\_surgery\_short-term | 0.21187 | VEDOLIZUMAB | 146,934 € | 6.024 QALY | 1,551,092 €/QALY |
| p\_surgery\_short-term | 0.23116 | ADALIMUMAB | 62,407 € | 5.159 QALY | 48,174 €/QALY |
| p\_surgery\_short-term | 0.23116 | GOLIMUMAB | 64,998 € | 5.163 QALY | 45,349 €/QALY |
| p\_surgery\_short-term | 0.23116 | INFLIXIMAB | 103,705 € | 6.016 QALY | --- |
| p\_surgery\_short-term | 0.23116 | VEDOLIZUMAB | 146,888 € | 6.044 QALY | 1,551,092 €/QALY |
| **VARIABLE NAME** | **VARIABLE VALUE** | **STRATEGY** | **COST** | **EFFICACY** | **ICER (vs BASE CASE)** |
| p\_surgery\_mid-term | 0.0015 | ADALIMUMAB | 62,769 € | 5.069 QALY | 45,424 €/QALY |
| p\_surgery\_mid-term | 0.0015 | GOLIMUMAB | 65,380 € | 5.070 QALY | 42,589 €/QALY |
| p\_surgery\_mid-term | 0.0015 | INFLIXIMAB | 103,803 € | 5.972 QALY | --- |
| p\_surgery\_mid-term | 0.0015 | VEDOLIZUMAB | 146,985 € | 6.000 QALY | 1,551,092 €/QALY |
| p\_surgery\_mid-term | 0.0017 | ADALIMUMAB | 62,768 € | 5.069 QALY | 45,435 €/QALY |
| p\_surgery\_mid-term | 0.0017 | GOLIMUMAB | 65,379 € | 5.070 QALY | 42,600 €/QALY |
| p\_surgery\_mid-term | 0.0017 | INFLIXIMAB | 103,803 € | 5.972 QALY | --- |
| p\_surgery\_mid-term | 0.0017 | VEDOLIZUMAB | 146,985 € | 6.000 QALY | 1,551,092 €/QALY |
| p\_surgery\_mid-term | 0.0019 | ADALIMUMAB | 62,767 € | 5.070 QALY | 45,446 €/QALY |
| p\_surgery\_mid-term | 0.0019 | GOLIMUMAB | 65,379 € | 5.071 QALY | 42,611 €/QALY |
| p\_surgery\_mid-term | 0.0019 | INFLIXIMAB | 103,803 € | 5.973 QALY | --- |
| p\_surgery\_mid-term | 0.0019 | VEDOLIZUMAB | 146,985 € | 6.000 QALY | 1,551,092 €/QALY |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| p\_surgery\_mid-term | 0.0021 | ADALIMUMAB | 62,766 € | 5.070 QALY | 45,457 €/QALY |
| p\_surgery\_mid-term | 0.0021 | GOLIMUMAB | 65,378 € | 5.071 QALY | 42,622 €/QALY |
| p\_surgery\_mid-term | 0.0021 | INFLIXIMAB | 103,803 € | 5.973 QALY | --- |
| p\_surgery\_mid-term | 0.0021 | VEDOLIZUMAB | 146,985 € | 6.001 QALY | 1,551,092 €/QALY |
| p\_surgery\_mid-term | 0.0023 | ADALIMUMAB | 62,766 € | 5.070 QALY | 45,468 €/QALY |
| p\_surgery\_mid-term | 0.0023 | GOLIMUMAB | 65,377 € | 5.072 QALY | 42,634 €/QALY |
| p\_surgery\_mid-term | 0.0023 | INFLIXIMAB | 103,803 € | 5.973 QALY | --- |
| p\_surgery\_mid-term | 0.0023 | VEDOLIZUMAB | 146,985 € | 6.001 QALY | 1,551,092 €/QALY |
| **VARIABLE NAME** | **VARIABLE VALUE** | **STRATEGY** | **COST** | **EFFICACY** | **ICER (vs BASE CASE)** |
| p\_surgery\_long-term | 0.00013 | ADALIMUMAB | 62,766 € | 5.070 QALY | 45,447 €/QALY |
| p\_surgery\_long-term | 0.00013 | GOLIMUMAB | 65,377 € | 5.071 QALY | 42,611 €/QALY |
| p\_surgery\_long-term | 0.00013 | INFLIXIMAB | 103,802 € | 5.973 QALY | --- |
| p\_surgery\_long-term | 0.00013 | VEDOLIZUMAB | 146,985 € | 6.000 QALY | 1,551,092 €/QALY |
| p\_surgery\_long-term | 0.00015 | ADALIMUMAB | 62,767 € | 5.070 QALY | 45,448 €/QALY |
| p\_surgery\_long-term | 0.00015 | GOLIMUMAB | 65,378 € | 5.071 QALY | 42,613 €/QALY |
| p\_surgery\_long-term | 0.00015 | INFLIXIMAB | 103,803 € | 5.973 QALY | --- |
| p\_surgery\_long-term | 0.00015 | VEDOLIZUMAB | 146,985 € | 6.000 QALY | 1,551,092 €/QALY |
| p\_surgery\_long-term | 0.00017 | ADALIMUMAB | 62,767 € | 5.070 QALY | 45,450 €/QALY |
| p\_surgery\_long-term | 0.00017 | GOLIMUMAB | 65,378 € | 5.071 QALY | 42,614 €/QALY |
| p\_surgery\_long-term | 0.00017 | INFLIXIMAB | 103,803 € | 5.973 QALY | --- |
| p\_surgery\_long-term | 0.00017 | VEDOLIZUMAB | 146,985 € | 6.000 QALY | 1,551,649 €/QALY |
| p\_surgery\_long-term | 0.00018 | ADALIMUMAB | 62,767 € | 5.070 QALY | 45,452 €/QALY |
| p\_surgery\_long-term | 0.00018 | GOLIMUMAB | 65,379 € | 5.071 QALY | 42,617 €/QALY |
| p\_surgery\_long-term | 0.00018 | INFLIXIMAB | 103,803 € | 5.973 QALY | --- |
| p\_surgery\_long-term | 0.00018 | VEDOLIZUMAB | 146,985 € | 6.000 QALY | 1,551,092 €/QALY |
| p\_surgery\_long-term | 0.0002 | ADALIMUMAB | 62,768 € | 5.070 QALY | 45,453 €/QALY |
| p\_surgery\_long-term | 0.0002 | GOLIMUMAB | 65,379 € | 5.071 QALY | 42,618 €/QALY |
| p\_surgery\_long-term | 0.0002 | INFLIXIMAB | 103,803 € | 5.973 QALY | --- |
| p\_surgery\_long-term | 0.0002 | VEDOLIZUMAB | 146,986 € | 6.001 QALY | 1,551,092 €/QALY |
| **VARIABLE NAME** | **VARIABLE VALUE** | **STRATEGY** | **COST** | **EFFICACY** | **ICER (vs BASE CASE)** |
| p\_COMPLICATIONS\_surgery | 0.012 | ADALIMUMAB | 62,242 € | 5.074 QALY | 45,859 €/QALY |
| p\_COMPLICATIONS\_surgery | 0.012 | GOLIMUMAB | 64,838 € | 5.075 QALY | 43,041 €/QALY |
| p\_COMPLICATIONS\_surgery | 0.012 | INFLIXIMAB | 103,549 € | 5.975 QALY | --- |
| p\_COMPLICATIONS\_surgery | 0.012 | VEDOLIZUMAB | 146,732 € | 6.002 QALY | 1,551,092 €/QALY |
| p\_COMPLICATIONS\_surgery | 0.0135 | ADALIMUMAB | 62,504 € | 5.072 QALY | 45,654 €/QALY |
| p\_COMPLICATIONS\_surgery | 0.0135 | GOLIMUMAB | 65,108 € | 5.073 QALY | 42,827 €/QALY |
| p\_COMPLICATIONS\_surgery | 0.0135 | INFLIXIMAB | 103,676 € | 5.974 QALY | --- |
| p\_COMPLICATIONS\_surgery | 0.0135 | VEDOLIZUMAB | 146,858 € | 6.001 QALY | 1,551,092 €/QALY |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| p\_COMPLICATIONS\_surgery | 0.015 | ADALIMUMAB | 62,765 € | 5.070 QALY | 45,451 €/QALY |
| p\_COMPLICATIONS\_surgery | 0.015 | GOLIMUMAB | 65,376 € | 5.071 QALY | 42,616 €/QALY |
| p\_COMPLICATIONS\_surgery | 0.015 | INFLIXIMAB | 103,802 € | 5.973 QALY | --- |
| p\_COMPLICATIONS\_surgery | 0.015 | VEDOLIZUMAB | 146,984 € | 6.000 QALY | 1,551,092 €/QALY |
| p\_COMPLICATIONS\_surgery | 0.0165 | ADALIMUMAB | 63,024 € | 5.068 QALY | 45,250 €/QALY |
| p\_COMPLICATIONS\_surgery | 0.0165 | GOLIMUMAB | 65,643 € | 5.069 QALY | 42,407 €/QALY |
| p\_COMPLICATIONS\_surgery | 0.0165 | INFLIXIMAB | 103,927 € | 5.972 QALY | --- |
| p\_COMPLICATIONS\_surgery | 0.0165 | VEDOLIZUMAB | 147,109 € | 6.000 QALY | 1,551,092 €/QALY |
| p\_COMPLICATIONS\_surgery | 0.018 | ADALIMUMAB | 63,282 € | 5.066 QALY | 45,051 €/QALY |
| p\_COMPLICATIONS\_surgery | 0.018 | GOLIMUMAB | 65,908 € | 5.067 QALY | 42,200 €/QALY |
| p\_COMPLICATIONS\_surgery | 0.018 | INFLIXIMAB | 104,051 € | 5.971 QALY | --- |
| p\_COMPLICATIONS\_surgery | 0.018 | VEDOLIZUMAB | 147,233 € | 5.999 QALY | 1,551,092 €/QALY |
| **VARIABLE NAME** | **VARIABLE VALUE** |  | **COST** | **EFFICACY** | **ICER (vs BASE CASE)** |
| p\_SUCCESS\_surgery | 0.33519 | ADALIMUMAB | 63,358 € | 5.065 QALY | 44,984 €/QALY |
| p\_SUCCESS\_surgery | 0.33519 | GOLIMUMAB | 65,988 € | 5.066 QALY | 42,129 €/QALY |
| p\_SUCCESS\_surgery | 0.33519 | INFLIXIMAB | 104,083 € | 5.970 QALY | --- |
| p\_SUCCESS\_surgery | 0.33519 | VEDOLIZUMAB | 147,265 € | 5.998 QALY | 1,551,649 €/QALY |
| p\_SUCCESS\_surgery | 0.37714 | ADALIMUMAB | 63,033 € | 5.068 QALY | 45,240 €/QALY |
| p\_SUCCESS\_surgery | 0.37714 | GOLIMUMAB | 65,652 € | 5.069 QALY | 42,397 €/QALY |
| p\_SUCCESS\_surgery | 0.37714 | INFLIXIMAB | 103,929 € | 5.972 QALY | --- |
| p\_SUCCESS\_surgery | 0.37714 | VEDOLIZUMAB | 147,111 € | 5.999 QALY | 1,551,092 €/QALY |
| p\_SUCCESS\_surgery | 0.4191 | ADALIMUMAB | 62,766 € | 5.070 QALY | 45,450 €/QALY |
| p\_SUCCESS\_surgery | 0.4191 | GOLIMUMAB | 65,378 € | 5.071 QALY | 42,615 €/QALY |
| p\_SUCCESS\_surgery | 0.4191 | INFLIXIMAB | 103,802 € | 5.973 QALY | --- |
| p\_SUCCESS\_surgery | 0.4191 | VEDOLIZUMAB | 146,985 € | 6.000 QALY | 1,551,092 €/QALY |
| p\_SUCCESS\_surgery | 0.46105 | ADALIMUMAB | 62,544 € | 5.071 QALY | 45,626 €/QALY |
| p\_SUCCESS\_surgery | 0.46105 | GOLIMUMAB | 65,148 € | 5.073 QALY | 42,798 €/QALY |
| p\_SUCCESS\_surgery | 0.46105 | INFLIXIMAB | 103,697 € | 5.973 QALY | --- |
| p\_SUCCESS\_surgery | 0.46105 | VEDOLIZUMAB | 146,879 € | 6.001 QALY | 1,551,092 €/QALY |
| p\_SUCCESS\_surgery | 0.503 | ADALIMUMAB | 62,355 € | 5.073 QALY | 45,774 €/QALY |
| p\_SUCCESS\_surgery | 0.503 | GOLIMUMAB | 64,954 € | 5.074 QALY | 42,953 €/QALY |
| p\_SUCCESS\_surgery | 0.503 | INFLIXIMAB | 103,607 € | 5.974 QALY | --- |
| p\_SUCCESS\_surgery | 0.503 | VEDOLIZUMAB | 146,789 € | 6.002 QALY | 1,551,092 €/QALY |